EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 22-Jun-2026 21:15 ET (23-Jun-2026 01:15 GMT/UTC)

27-May-2026

Mount Sinai researchers to present expansive range of cancer research at 2026 ASCO Annual Meeting

The Mount Sinai Hospital / Mount Sinai School of Medicine
Meeting Announcement

Researchers and clinicians from the Mount Sinai Tisch Cancer Center will present new research at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place Friday, May 29, through Tuesday, June 2, at McCormick Place in Chicago.

Mount Sinai investigators will contribute to presentations across multiple cancer specialties, including hematologic malignancies, thoracic oncology, urothelial cancer, gynecologic oncology, translational science, and cancer care delivery.

27-May-2026

ASCO: UT MD Anderson faculty honored as 2026 Special Award recipients

University of Texas M. D. Anderson Cancer Center
Grant and Award Announcement

CHICAGO, MAY 27, 2026 ― In honor of their outstanding contributions to oncology, Sharon Giordano, M.D., chair of Breast Medical Oncology, and Eduardo Vilar-Sanchez, M.D., Ph.D., chair ad interim of Clinical Cancer Prevention, from The University of Texas MD Anderson Cancer Center will receive Special Awards at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Meeting: ASCO Annual Meeting 2026

27-May-2026

Colorectal cancer risk linked to gut microbiome alterations

Harvard T.H. Chan School of Public Health
Peer-Reviewed Publication

More than a decade after removal of an adenoma—a precancerous mass—from the colon, alterations to the gut microbiome and metabolites remain and may drive heightened risk of colorectal cancer (CRC), according to a new study led by researchers at Harvard T.H. Chan School of Public Health. The study also found that diet and physical activity were more closely tied to the abundance of these CRC-associated gut microbes in people with a history of adenoma than in adenoma-free individuals, suggesting lifestyle may play a particularly important role in shaping these microbes in this high-risk group.

Journal: Cell Host & Microbe
Funder: team OPTIMISTICC, Prescient Metabiomics, Cancer Research UK, Cancer Research UK, American Cancer Society

27-May-2026

Wistar Institute and Temple scientists identify metabolic target to overcome chemotherapy resistance in ovarian cancer

The Wistar Institute
Peer-Reviewed Publication

For the first time, researchers have shown that a new metabolic process is altered in cancer cells that makes them resistant to DNA-damaging agents.

Journal: Nature
Funder: Cancer Center Support Grant, Sandy Rollman Ovarian Cancer Foundation, American Cancer Society, Ovarian Cancer Research Alliance, Congressionally Directed Medical Research Program, HERA Ovarian Cancer Foundation, Melanoma Research Foundation, Janet Burroughs Ovarian Cancer Foundation, Hollings Cancer Center Abney Graduate Fellowship, Hevolution Foundation, Einstein-Mount Sinai Diabetes Center, UPMC Hillman Cancer Center, The Wistar Institute

27-May-2026

First comprehensive look at breast cancer in Native American women reveals key genetic differences

University of Notre Dame
Peer-Reviewed Publication

Researchers from the University of Notre Dame have published the first known detailed study of breast cancer tissue from Native American women. The study, published in npj Precision Oncology, reveals important molecular differences that may impact the efficacy of therapies for female, Native American breast cancer patients.

Journal: npj Precision Oncology
Funder: U.S. Department of Defense

27-May-2026

KRAS degradation induces rapid lung cancer regression in preclinical mouse models

Institute for Research in Biomedicine (IRB Barcelona)
Peer-Reviewed Publication

A study by IRB Barcelona and Centro de Investigación del Cáncer in Salamanca demonstrates that eliminating mutated KRAS protein using PROTACs induces rapid tumour regression in mouse models of lung adenocarcinoma.

The work identifies resistance mechanisms distinct from those observed with classic KRAS inhibitors, a relevant finding as the first KRAS degraders are already in clinical trials.

Published in Cancer Research, the developed model could help evaluate future targeted protein degradation-based therapies against other oncoproteins.

Journal: Cancer Research

27-May-2026

Research alert: Naturally occurring molecule may help outsmart melanoma

University of California - San Diego
Peer-Reviewed Publication

Researchers from UC San Diego have uncovered a new possibility for treating melanoma, and it's something we have in our bodies already.

Journal: Oncogenesis

27-May-2026

Milestone in leukemia research: Dresden long-term study shows potential to significantly influence the course of blood cancer

Technische Universität Dresden
Peer-Reviewed Publication

With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden University Medicine for the treatment of leukemia patients, has reached an important milestone. The results demonstrate the potential of early, minimal residual disease (MRD)-guided therapy to delay or possibly prevent relapses. RELAZA2 is considered the world’s first MRD-triggered prospective study in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Journal: Blood

27-May-2026

Want to stay current on latest in cancer prevention and treatment? Free service from NCCN can help

National Comprehensive Cancer Network
Business Announcement

Weekly updates from NCCN share every time a change is made to evidence-based, expert consensus-driven guidelines for cancer prevention, screening, treatment, and supportive care. Learn more at NCCN.org/updates.

27-May-2026

Lung cancer cells switch identity to resist treatment

University of Southampton
Peer-Reviewed Publication

Cancer scientists have discovered that lung cancer cells can change their identity to resist treatment.

Journal: Molecular Oncology